{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:44:36Z","timestamp":1794573876350,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The first vaccine against chikungunya virus (CHIKV) has now been licensed; however, due to a limited knowledge of the underlying global burden, its potential to reduce disease burden remains unknown. We used data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying CHIKV burden in 180 countries and territories, and we explored the potential impact of vaccination campaigns. We estimate that 104 countries have experienced CHIKV transmission, covering 2.8 billion people, and that, in epidemic settings, the mean duration between outbreaks is 6.2\u2009years, with 8.4% of the susceptible population infected per outbreak. Globally, there are 35 million annual infections, mainly in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% and a protection against infection of 40%, vaccinating 50% of individuals over 12\u2009years of age in places and times where the virus circulates would avert 4,436 infections, 0.34 deaths and 37 disability-adjusted life years per 100,000 doses used. These findings highlight the global burden of chikungunya and the potential of CHIKV vaccination campaigns.<\/jats:p>","DOI":"10.1038\/s41591-025-03703-w","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:04:04Z","timestamp":1749531844000},"page":"2342-2349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-8755","authenticated-orcid":false,"given":"Gabriel","family":"Ribeiro dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariha","family":"Jawed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-5505","authenticated-orcid":false,"given":"Arminder","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Scarponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard E. G.","family":"Mboera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Seruyange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-0011","authenticated-orcid":false,"given":"Mathieu J. P.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bosomprah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-4925","authenticated-orcid":false,"given":"Augustine O.","family":"Udeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koussay","family":"Dellagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael","family":"Hoz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-6747","authenticated-orcid":false,"given":"Jaffu","family":"Chilongola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1038","authenticated-orcid":false,"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-4549","authenticated-orcid":false,"given":"Simon","family":"Cauchemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3626-4254","authenticated-orcid":false,"given":"Henrik","family":"Salje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"3703_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2015.04.016","volume":"120","author":"SC Weaver","year":"2015","unstructured":"Weaver, S. C. & Forrester, N. L. Chikungunya: evolutionary history and recent epidemic spread. Antivir. Res. 120, 32\u201339 (2015).","journal-title":"Antivir. Res."},{"key":"3703_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.coviro.2016.02.007","volume":"16","author":"KA Tsetsarkin","year":"2016","unstructured":"Tsetsarkin, K. A., Chen, R. & Weaver, S. C. Interspecies transmission and chikungunya virus emergence. Curr. Opin. Virol. 16, 143\u2013150 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"3703_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2021.08.066","volume":"112","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll, M., Salje, H., Chang, A. Y. & Watson, H. Arthralgia resolution rate following chikungunya virus infection. Int. J. Infect. Dis. 112, 1\u20137 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"3703_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","volume":"24","author":"H Kang","year":"2024","unstructured":"Kang, H. et al. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study. Lancet Infect. Dis. 24, 488\u2013503 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3703_CR5","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2666-5247(23)00033-2","volume":"4","author":"WM de Souza","year":"2023","unstructured":"de Souza, W. M. et al. Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological study. Lancet Microbe 4, e319\u2013e329 (2023).","journal-title":"Lancet Microbe"},{"key":"3703_CR6","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Estigarribia, P. E. et al. Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03684-w (2025).","DOI":"10.1038\/s41591-025-03684-w"},{"key":"3703_CR7","doi-asserted-by":"crossref","unstructured":"Lim, A. et al. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever. Nat. Commun. 16, 3418 (2025).","DOI":"10.1038\/s41467-025-58609-5"},{"key":"3703_CR8","doi-asserted-by":"crossref","unstructured":"Kyungah Lim, J. et al. Seroepidemiological reconstruction of long-term chikungunya virus circulation in Burkina Faso and Gabon. J. Infect. Dis. 221, 261\u2013267 (2023).","DOI":"10.1093\/infdis\/jiac246"},{"key":"3703_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/infdis\/jiv470","volume":"213","author":"H Salje","year":"2016","unstructured":"Salje, H. et al. Reconstruction of 60 years of chikungunya epidemiology in the Philippines demonstrates episodic and focal transmission. J. Infect. Dis. 213, 604\u2013610 (2016).","journal-title":"J. Infect. Dis."},{"key":"3703_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.vaccine.2022.11.028","volume":"41","author":"QM Tran","year":"2023","unstructured":"Tran, Q. M. et al. Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling. Vaccine 41, 182\u2013192 (2023).","journal-title":"Vaccine"},{"key":"3703_CR11","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/S2666-5247(20)30175-0","volume":"2","author":"MS Kumar","year":"2021","unstructured":"Kumar, M. S. et al. Seroprevalence of chikungunya virus infection in India, 2017: a cross-sectional population-based serosurvey. Lancet Microbe 2, e41\u2013e47 (2021).","journal-title":"Lancet Microbe"},{"key":"3703_CR12","unstructured":"U.S. Food and Drug Administration, Office of the Commissioner. FDA approves first vaccine to prevent disease caused by chikungunya virus. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus (2023)."},{"key":"3703_CR13","unstructured":"Valneva receives marketing authorization in Europe for the world\u2019s first chikungunya vaccine, IXCHIQ\u00ae. https:\/\/valneva.com\/press-release\/valneva-receives-marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq\/ (2024)."},{"key":"3703_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/tropicalmed8060301","volume":"8","author":"LB Costa","year":"2023","unstructured":"Costa, L. B. et al. Epidemiology and economic burden of chikungunya: a systematic literature review. Trop. Med. Infect. Dis. 8, 301 (2023).","journal-title":"Trop. Med. Infect. Dis."},{"key":"3703_CR15","unstructured":"More than US$ 1.8 billion in support for African vaccine manufacturing, catching up missed children and pandemic preparedness approved as Gavi Board steps up efforts to tackle backsliding and fight health emergencies. https:\/\/www.gavi.org\/news\/media-room\/initiatives-african-vaccine-manufacturing-approved-gavi-board (2023)."},{"key":"3703_CR16","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1111\/jgs.15492","volume":"66","author":"L Godaert","year":"2018","unstructured":"Godaert, L. et al. Misdiagnosis of chikungunya virus infection: comparison of old and younger adults. J. Am. Geriatr. Soc. 66, 1768\u20131772 (2018).","journal-title":"J. Am. Geriatr. Soc."},{"key":"3703_CR17","doi-asserted-by":"crossref","unstructured":"Kang, H. et al. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability in endemic and epidemic settings: systematic review, meta-analysis, and modelling study. Lancet Infect. Dis. 24, 488\u2013503 (2024).","DOI":"10.1016\/S1473-3099(23)00810-1"},{"key":"3703_CR18","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08347","volume":"4","author":"MUG Kraemer","year":"2015","unstructured":"Kraemer, M. U. G. et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. eLife 4, e08347 (2015).","journal-title":"eLife"},{"key":"3703_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.1","volume":"4","author":"CT Lloyd","year":"2017","unstructured":"Lloyd, C. T., Sorichetta, A. & Tatem, A. J. High resolution global gridded data for use in population studies. Sci. Data 4, 170001 (2017).","journal-title":"Sci. Data"},{"key":"3703_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/21645515.2016.1245250","volume":"13","author":"SN Desai","year":"2017","unstructured":"Desai, S. N. et al. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. Hum. Vaccin. Immunother. 13, 579\u2013587 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"3703_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2014.4","volume":"1","author":"JP Messina","year":"2014","unstructured":"Messina, J. P. et al. A global compendium of human dengue virus occurrence. Sci. Data 1, 140004 (2014).","journal-title":"Sci. Data"},{"key":"3703_CR22","doi-asserted-by":"crossref","unstructured":"Halstead, S. B. Dengue. Lancet 370, 1644\u20131652 (2007).","DOI":"10.1016\/S0140-6736(07)61687-0"},{"key":"3703_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011307","volume":"19","author":"M Novelo","year":"2023","unstructured":"Novelo, M. et al. Dengue and chikungunya virus loads in the mosquito Aedes aegypti are determined by distinct genetic architectures. PLoS Pathog. 19, e1011307 (2023).","journal-title":"PLoS Pathog."},{"key":"3703_CR24","doi-asserted-by":"publisher","first-page":"e0007213","DOI":"10.1371\/journal.pntd.0007213","volume":"13","author":"SJ Ryan","year":"2019","unstructured":"Ryan, S. J., Carlson, C. J., Mordecai, E. A. & Johnson, L. R. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl. Trop. Dis. 13, e0007213 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3703_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1473-3099(24)00029-X","volume":"24","author":"H Salje","year":"2024","unstructured":"Salje, H. & Cort\u00e9s Azuero, O. The deadly potential of chikungunya virus. Lancet Infect. Dis. 24, 442\u2013444 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3703_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S1473-3099(23)00739-9","volume":"24","author":"T Cerqueira-Silva","year":"2024","unstructured":"Cerqueira-Silva, T. et al. Risk of death following chikungunya virus disease in the 100 Million Brazilian Cohort, 2015\u20132018: a matched cohort study and self-controlled case series. Lancet Infect. Dis. 24, 504\u2013513 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3703_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003764","volume":"9","author":"I-K Yoon","year":"2015","unstructured":"Yoon, I.-K. et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl. Trop. Dis. 9, e0003764 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3703_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.4269\/ajtmh.18-0437","volume":"99","author":"MJ Hennessey","year":"2018","unstructured":"Hennessey, M. J. et al. Seroprevalence and symptomatic attack rate of chikungunya virus infection, United States Virgin Islands, 2014\u20132015. Am. J. Trop. Med. Hyg. 99, 1321\u20131326 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3703_CR29","doi-asserted-by":"publisher","first-page":"e3066","DOI":"10.1371\/journal.pone.0003066","volume":"3","author":"D Sissoko","year":"2008","unstructured":"Sissoko, D. et al. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005\u20132006: a population-based survey. PLoS ONE 3, e3066 (2008).","journal-title":"PLoS ONE"},{"key":"3703_CR30","doi-asserted-by":"crossref","unstructured":"Bustos Carrillo, F. et al. Epidemiological evidence for lineage-specific differences in the risk of inapparent chikungunya virus infection. J. Virol. 93, e01622-18 (2019).","DOI":"10.1128\/JVI.01622-18"},{"key":"3703_CR31","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1016\/j.vaccine.2018.10.033","volume":"37","author":"GN Milligan","year":"2019","unstructured":"Milligan, G. N., Schnierle, B. S., McAuley, A. J. & Beasley, D. W. C. Defining a correlate of protection for chikungunya virus vaccines. Vaccine 37, 7427\u20137436 (2019).","journal-title":"Vaccine"},{"key":"3703_CR32","unstructured":"Valneva reports positive 12-month antibody persistence data for single-shot chikungunya vaccine candidate. https:\/\/valneva.com\/press-release\/valneva-reports-positive-12-month-antibody-persistence-data-for-single-shot-chikungunya-vaccine-candidate\/ (2022)."},{"key":"3703_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S1473-3099(24)00357-8","volume":"24","author":"R McMahon","year":"2024","unstructured":"McMahon, R. et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infect. Dis. 24, 1383\u20131392 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3703_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijid.2020.03.073","volume":"95","author":"I-K Yoon","year":"2020","unstructured":"Yoon, I.-K. et al. Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort. Int. J. Infect. Dis. 95, 167\u2013173 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"3703_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1473-3099(24)00458-4","volume":"25","author":"V Buerger","year":"2025","unstructured":"Buerger, V. et al. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents. Lancet Infect. Dis. 25, 114\u2013125 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"3703_CR36","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","volume":"401","author":"M Schneider","year":"2023","unstructured":"Schneider, M. et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 401, 2138\u20132147 (2023).","journal-title":"Lancet"},{"key":"3703_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011948","volume":"18","author":"CM Warnes","year":"2024","unstructured":"Warnes, C. M. et al. Longitudinal analysis of post-acute chikungunya-associated arthralgia in children and adults: a prospective cohort study in Managua, Nicaragua (2014\u20132018). PLoS Negl. Trop. Dis. 18, e0011948 (2024).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3703_CR38","first-page":"849","volume":"66","author":"E Bright","year":"2000","unstructured":"Bright, E., Coleman, P. & Dobson, J. E. LandScan: a global population database for estimating populations at risk. Photogramm. Eng. Remote Sens. 66, 849\u2013858 (2000).","journal-title":"Photogramm. Eng. Remote Sens."},{"key":"3703_CR39","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(18)30994-2","volume":"391","author":"N Fullman","year":"2018","unstructured":"Fullman, N. et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet 391, 2236\u20132271 (2018).","journal-title":"Lancet"},{"key":"3703_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v069.i12","volume":"69","author":"AA King","year":"2016","unstructured":"King, A. A., Nguyen, D. & Ionides, E. L. Statistical inference for partially observed Markov processes via the R package pomp. J. Stat. Softw. 69, 1\u201343 (2016).","journal-title":"J. Stat. Softw."},{"key":"3703_CR41","unstructured":"United Nations. Department of Economic Development and Social Affairs, Population Division. World Population Prospects. https:\/\/population.un.org\/wpp\/"},{"key":"3703_CR42","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.onehlt.2022.100427","volume":"15","author":"OM Man","year":"2022","unstructured":"Man, O. M., Fuller, T. L., Rosser, J. I. & Nielsen-Saines, K. Re-emergence of arbovirus diseases in the State of Rio de Janeiro, Brazil: the role of simultaneous viral circulation between 2014 and 2019. One Health 15, 100427 (2022).","journal-title":"One Health"},{"key":"3703_CR43","first-page":"299","volume":"69","author":"E Bautista-Reyes","year":"2017","unstructured":"Bautista-Reyes, E., N\u00fa\u00f1ez-Avellaneda, D., Alonso-Palomares, L. A. & Salazar, M. I. Chikungunya: molecular aspects, clinical outcomes and pathogenesis. Rev. Invest. Clin. 69, 299\u2013307 (2017).","journal-title":"Rev. Invest. Clin."},{"key":"3703_CR44","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1408509","volume":"371","author":"DM Morens","year":"2014","unstructured":"Morens, D. M. & Fauci, A. S. Chikungunya at the door\u2014d\u00e9j\u00e0 vu all over again? N. Engl. J. Med. 371, 885\u2013887 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3703_CR45","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.40384","volume":"70","author":"AY Chang","year":"2018","unstructured":"Chang, A. Y. et al. Frequency of chronic joint pain following chikungunya virus infection: a Colombian cohort study. Arthritis Rheumatol. 70, 578\u2013584 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"3703_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jiph.2015.06.001","volume":"8","author":"JA Cardona-Ospina","year":"2015","unstructured":"Cardona-Ospina, J. A., Rodriguez-Morales, A. J. & Villamil-G\u00f3mez, W. E. The burden of chikungunya in one coastal department of Colombia (Sucre): estimates of the disability adjusted life years (DALY) lost in the 2014 epidemic. J. Infect. Public Health 8, 644\u2013646 (2015).","journal-title":"J. Infect. Public Health"},{"key":"3703_CR47","doi-asserted-by":"publisher","first-page":"e0009055","DOI":"10.1371\/journal.pntd.0009055","volume":"15","author":"CJ Puntasecca","year":"2021","unstructured":"Puntasecca, C. J., King, C. H. & LaBeaud, A. D. Measuring the global burden of chikungunya and Zika viruses: a systematic review. PLoS Negl. Trop. Dis. 15, e0009055 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3703_CR48","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3201\/eid2304.161562","volume":"23","author":"LR Feldstein","year":"2017","unstructured":"Feldstein, L. R. et al. Persistent arthralgia associated with chikungunya virus outbreak, US Virgin Islands, December 2014\u2013February 2016. Emerg. Infect. Dis. 23, 673\u2013676 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"3703_CR49","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"JA Salomon","year":"2015","unstructured":"Salomon, J. A. et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob. Health 3, e712\u2013e723 (2015).","journal-title":"Lancet Glob. Health"},{"key":"3703_CR50","doi-asserted-by":"publisher","first-page":"e1918","DOI":"10.1371\/journal.pntd.0001918","volume":"6","author":"D Ruiz-Moreno","year":"2012","unstructured":"Ruiz-Moreno, D., Vargas, I. S., Olson, K. E. & Harrington, L. C. Modeling dynamic introduction of chikungunya virus in the United States. PLoS Negl. Trop. Dis. 6, e1918 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3703_CR51","doi-asserted-by":"publisher","unstructured":"B\u00e1ez-Hern\u00e1ndez, N., Casas-Mart\u00ednez, M., Danis-Lozano, R. & Velasco-Hern\u00e1ndez, J. X. A mathematical model for Dengue and Chikungunya in Mexico. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/122556 (2017).","DOI":"10.1101\/122556"},{"key":"3703_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(07)70107-X","volume":"7","author":"G Pialoux","year":"2007","unstructured":"Pialoux, G., Ga\u00fcz\u00e8re, B.-A., Jaur\u00e9guiberry, S. & Strobel, M. Chikungunya, an epidemic arbovirosis. Lancet Infect. Dis. 7, 319\u2013327 (2007).","journal-title":"Lancet Infect. Dis."},{"key":"3703_CR53","first-page":"003","volume":"2","author":"HM Yaseen","year":"2012","unstructured":"Yaseen, H. M., Simon, F., Deparis, X. & Marimoutou, C. Estimation of lasting impact of a chikungunya outbreak in Reunion Island. Epidemiology: Open Access 2, 003 (2012).","journal-title":"Epidemiology: Open Access"},{"key":"3703_CR54","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/tmi.13711","volume":"27","author":"ERN Vidal","year":"2022","unstructured":"Vidal, E. R. N., Frutuoso, L. C. V., Duarte, E. C. & Peixoto, H. M. Epidemiological burden of chikungunya fever in Brazil, 2016 and 2017. Trop. Med. Int. Health 27, 174\u2013184 (2022).","journal-title":"Trop. Med. Int. Health"}],"updated-by":[{"DOI":"10.1038\/s41591-025-04065-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03703-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:02:21Z","timestamp":1762848141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03703-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03703-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-04065-z","URL":"https:\/\/doi.org\/10.1038\/s41591-025-04065-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S. has received consultancy payments from Gavi and from Valneva in support of Phase IV trial design. G.R.d.S. has received consultancy payments from Valneva in support of Phase IV trial design. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}